Understanding the ACURATE neo2 TAVI Withdrawal: Key Insights
Boston Scientific has withdrawn the ACURATE neo2 TAVI series, a decision likely reflective of testing challenges rather than the valve’s quality. Prior trials revealed suboptimal performance and increased patient risks, potentially due to operator inexperience and inadequate patient selection. The learning curve for this device may have influenced outcomes, warranting improved trial designs in the future.
CARDiOmics Club 